Suzhou HepaThera Biotech Co., Ltd.

Biotech

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

2 drugs in development

Phase 11

By Therapeutic Area

top 1

Infectious Disease

2100%

R&D Momentum

18/100

Pipeline Velocity

6/100

Trial Completion Rate

100/100

Pipeline Concentration

100/100

Pipeline Freshness

89/100

Activity

Key Events

Nov 5, 2025TrialA Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection

Dec 30, 2024TrialA Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection

Jun 12, 2023TrialPhase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients with Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (only in Participants with Chronic HBV Infection)

Nov 22, 2022TrialThis is a Phase 1 Study in Which Healthy Volunteers and Participants with Chronic HBV Infection Will Receive HT-101 or Placebo and Will Be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Infectious Disease

Chronic Hepatitis

HT-102

Chronic Hepatitis B Virus Infection

HT-101 HT-102

Infectious Disease

Chronic Hepatitis

HT-102Phase 1

Chronic Hepatitis B Virus Infection

HT-101Phase 2

HT-102Phase 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)